259 related articles for article (PubMed ID: 31992357)
1. Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma.
Wu T; Zhang ZW; Li S; Wang B; Yang Z; Li P; Zhang J; Tong WM; Li C; Zhao F; Niu Y; Liu P
Clin Epigenetics; 2020 Jan; 12(1):19. PubMed ID: 31992357
[TBL] [Abstract][Full Text] [Related]
2. Posterior fossa ependymoma: current insights.
Thompson YY; Ramaswamy V; Diamandis P; Daniels C; Taylor MD
Childs Nerv Syst; 2015 Oct; 31(10):1699-706. PubMed ID: 26351223
[TBL] [Abstract][Full Text] [Related]
3. DNA 5-hydroxymethylcytosine in pediatric central nervous system tumors may impact tumor classification and is a positive prognostic marker.
Azizgolshani N; Petersen CL; Chen Y; Levy JJ; Salas LA; Perreard L; Nguyen LN; Christensen BC
Clin Epigenetics; 2021 Sep; 13(1):176. PubMed ID: 34538273
[TBL] [Abstract][Full Text] [Related]
4. Medulloblastoma and ependymoma cells display increased levels of 5-carboxylcytosine and elevated
Ramsawhook A; Lewis L; Coyle B; Ruzov A
Clin Epigenetics; 2017; 9():18. PubMed ID: 28228863
[TBL] [Abstract][Full Text] [Related]
5. Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort.
Jünger ST; Mynarek M; Wohlers I; Dörner E; Mühlen AZ; Velez-Char N; von Hoff K; Rutkowski S; Warmuth-Metz M; Kortmann RD; Timmermann B; Rahmann S; Klein-Hitpass L; von Bueren AO; Pietsch T
Acta Neuropathol Commun; 2019 Nov; 7(1):181. PubMed ID: 31727173
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
[TBL] [Abstract][Full Text] [Related]
7. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas.
Godfraind C; Kaczmarska JM; Kocak M; Dalton J; Wright KD; Sanford RA; Boop FA; Gajjar A; Merchant TE; Ellison DW
Acta Neuropathol; 2012 Aug; 124(2):247-57. PubMed ID: 22526017
[TBL] [Abstract][Full Text] [Related]
8. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer.
Storebjerg TM; Strand SH; Høyer S; Lynnerup AS; Borre M; Ørntoft TF; Sørensen KD
Clin Epigenetics; 2018 Aug; 10(1):105. PubMed ID: 30086793
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity within the PF-EPN-B ependymoma subgroup.
Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
[TBL] [Abstract][Full Text] [Related]
10. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
[TBL] [Abstract][Full Text] [Related]
12. Establishment of patient-derived orthotopic xenograft model of 1q+ posterior fossa group A ependymoma.
Pierce AM; Witt DA; Donson AM; Gilani A; Sanford B; Sill M; Van Court B; Oweida A; Prince EW; Steiner J; Danis E; Dorris K; Hankinson T; Handler MH; Jones KL; Karam SD; Serkova NJ; Vibhakar R; Foreman NK; Griesinger AM
Neuro Oncol; 2019 Dec; 21(12):1540-1551. PubMed ID: 31276586
[TBL] [Abstract][Full Text] [Related]
13. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
[TBL] [Abstract][Full Text] [Related]
14. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.
Ahsan S; Raabe EH; Haffner MC; Vaghasia A; Warren KE; Quezado M; Ballester LY; Nazarian J; Eberhart CG; Rodriguez FJ
Acta Neuropathol Commun; 2014 Jun; 2():59. PubMed ID: 24894482
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and microRNA profile analysis for CD44 positive expression pediatric posterior fossa ependymoma.
Shu C; Wang Q; Yan X; Wang J
Clin Transl Oncol; 2018 Nov; 20(11):1439-1447. PubMed ID: 29704232
[TBL] [Abstract][Full Text] [Related]
16. Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood.
Amani V; Donson AM; Lummus SC; Prince EW; Griesinger AM; Witt DA; Hankinson TC; Handler MH; Dorris K; Vibhakar R; Foreman NK; Hoffman LM
J Neuropathol Exp Neurol; 2017 Jul; 76(7):595-604. PubMed ID: 28863455
[TBL] [Abstract][Full Text] [Related]
17. Recurrent pediatric infratentorial ependymomas: a systematic review and meta-analysis on outcomes and molecular classification.
Montgomery EY; Thirunavu V; Pagadala M; Shlobin NA; Plant-Fox AS; Lam S; DeCuypere M
J Neurosurg Pediatr; 2023 Feb; 31(2):132-142. PubMed ID: 36433871
[TBL] [Abstract][Full Text] [Related]
18. TET2 promotor methylation and TET2 protein expression in pediatric posterior fossa ependymoma.
Pierscianek D; Teuber-Hanselmann S; Ahmadipour Y; Darkwah Oppong M; Unteroberdörster M; Müller O; Jabbarli R; Sure U; Zhu Y; El Hindy N
Neuropathology; 2020 Apr; 40(2):138-143. PubMed ID: 31777116
[TBL] [Abstract][Full Text] [Related]
19. Loss of 5-Hydroxymethylcytosine as an Epigenetic Signature That Correlates With Poor Outcomes in Patients With Medulloblastoma.
Zhao F; Zhang ZW; Zhang J; Zhang S; Zhang H; Zhao C; Chen Y; Luo L; Tong WM; Li C; Niu Y; Liu P
Front Oncol; 2021; 11():603686. PubMed ID: 33718152
[TBL] [Abstract][Full Text] [Related]
20. Understanding the Deadly Silence of Posterior Fossa A Ependymoma.
Lin GL; Monje M
Mol Cell; 2020 Jun; 78(6):999-1001. PubMed ID: 32559429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
